Outcomes of Lenalidomide Relapsed/Refractory Patients
Haematology International Journal · 2026 · 10 (1) · 1-7
DOI: 10.23880/hij-16000274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haematology International Journal, 2026. Verfasst von Gkioka AI und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Lenalidomide constitutes a key component of therapeutic strategies for multiple myeloma (MM), both in combination with dexamethasone and as maintenance treatment. However, patients exhibit substantial heterogeneity in response and duration of benefit. In order to focus only on the benefit of Lenalidomide, we retrospectively analyzed 186 MM patients treated with doublet, lenalidomide–dexamethasone (n=158) and lenalidomide maintenance post-ASCT (n=18). Patients were stratified into five groups based on time to progression: primary refractory (PRMM), very resistant (VRMM), resistant (ResMM), initially sensitive (ISMM), and long-lasting responders (RALR). Median overall survival after lenalidomide (LenOS) varied markedly: PRMM 2 months, VRMM 8 months, ResMM 12 months, ISMM 39 months, and RALR 106 months (p
Zitieren
APA
AI, G., A, G., G, O., A, K., V, B., E, N., P, P., & MC, K. (2026). Outcomes of Lenalidomide Relapsed/Refractory Patients. Haematology International Journal, 10(1), 1-7. https://doi.org/10.23880/hij-16000274
Vancouver
AI G, A G, G O, A K, V B, E N, et al. Outcomes of Lenalidomide Relapsed/Refractory Patients. Haematology International Journal. 2026;10(1):1-7. doi:10.23880/hij-16000274
BibTeX
@article{AI2026,
author = {AI, Gkioka and A, Gkiokas and G, Oikonomou and A, Koudouna and V, Bartzi and E, Nikolaou and P, Panayiotidis and MC, Kyrtsonis},
title = {Outcomes of Lenalidomide Relapsed/Refractory Patients},
journal = {Haematology International Journal},
year = {2026},
volume = {10},
number = {1},
pages = {1--7},
doi = {10.23880/hij-16000274}
}
EUVIMED